Angiotensin receptor blockers regulate the synchronization of circadian rhythms in heart rate and blood pressure

Journal of Hypertension

Volumn 31, Issue 6, 2013, Pages 1233-1238

  Sato, Ryo ^a   Mizuno, Masashi ^a   Miura, Toshiyuki ^a   Kato, Yoko ^a   Watanabe, Shuichi ^a   Fuwa, Daisuke ^a   Ogiyama, Yoshiaki ^a   Tomonari, Tatsuya ^a   Ota, Keisuke ^a   Ichikawa, Tadashi ^a   Shirasawa, Yuichi ^a   Ito, Akinori ^a   Yoshida, Atsuhiro ^a   Fukuda, Michio ^a   Kimura, Genjiro ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Asahi Rosai Hospital   (Japan)

Author keywords

angiotensin II receptor blocker; chronic kidney disease; heart rate variability; renin angiotensin system inhibitors; sympathetic nervous system

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; OLMESARTAN;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; BLOOD PRESSURE; CHRONIC KIDNEY DISEASE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CREATININE CLEARANCE; DETERIORATION; DIASTOLIC BLOOD PRESSURE; FEMALE; GLOMERULUS FILTRATION RATE; HEART RATE VARIABILITY; HUMAN; KIDNEY FUNCTION; MALE; MEAN ARTERIAL PRESSURE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; URINALYSIS; URINARY EXCRETION;

EID: 84877576937     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32836043c9     Document Type: Article

References (29)

1. Fukuda M, Munemura M, Usami T, Nakao N, Takeuchi O, Kamiya Y, et al. Nocturnal blood pressure is elevated with natriuresis and proteinuria as renal function deteriorates in nephropathy. Kidney Int 2004; 65:621-625.
2. Fukuda M, Mizuno M, Yamanaka T, Motokawa M, Shirasawa Y, Nishio T, et al. Patients with renal dysfunction require a longer duration until blood pressure dips during the night. Hypertension 2008; 52:1155-1160.
3. Kimura G. Kidney and circadian blood pressure rhythm. Hypertension 2008; 51:827-828.
4. Hansen TW, Thijs L, Boggia J, Kikuya M, Björklund-Bodegard K, Richart T, et al. International Database on Ambulatory Blood Pressure in Relation to Cardiovascular Outcomes Investigators. Prognostic value of ambulatory heart rate revisited in 6928 subjects from 6 populations. Hypertension 2008; 52:229-235.
5. Hozawa A, Inoue R, Ohkubo T, Kikuya M, Metoki H, Asayama K, et al. Predictive value of ambulatory heart rate in the Japanese general population: the Ohasama study. J Hypertens 2008; 26:1571-1576.
6. Ben-Dov IZ, Kark JD, Ben-Ishay D, Mekler J, Ben-Arie L, Bursztyn M. Blunted heart rate dip during sleep and all-cause mortality. Arch Intern Med 2007; 167:2116-2121.
7. Eguchi K, Hoshide S, Ishikawa J, Pickering TG, Schwartz JE, Shimada K, Kario K. Nocturnal nondipping of heart rate predicts cardiovascular events in hypertensive patients. J Hypertens 2009; 27:2265-2270.
8. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension 2000; 36:901-906.
9. Grassi G, Quarti-Trevano F, Seravalle G, Arenare F, Volpe M, Furiani S, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension 2011; 57:846-851.
10. Hering D, Zdrojewski Z, Krol E, Kara T, Kucharska W, Somers VK, et al. Tonic chemoreflex activation contributes to the elevated muscle sympathetic nerve activity in patients with chronic renal failure. J Hypertens 2007; 25:157-161.
11. Siddiqi L, Joles JA, Grassi G, Blankestijn PJ. Is kidney ischemia the central mechanism in parallel activation of the renin and sympathetic system? J Hypertens 2009; 27:1341-1349.
12. Malik M, Camm AJ. Components of heart rate variability: what they really mean and what we really measure. Am J Cardiol 1993; 72:821-822.
13. Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 1996; 93:1043-1065.
14. Ligtenberg G, Blankestijn PJ, Oey PL, Klein IH, Dijkhorst-Oei LT, Boomsma F, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999; 340:1321-1328.
15. Klein IH, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol 2003; 14:425-430.
16. Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant 2011; 26:2930-2934.
17. Fukuda M, Yamanaka T, Mizuno M, Motokawa M, Shirasawa Y, Miyagi S, et al. Angiotensin II type 1 receptor blocker, olmesartan, restores nocturnal blood pressure decline by enhancing daytime natriuresis. J Hypertens 2008; 26:583-588.
18. Fukuda M, Wakamatsu-Yamanaka T, Mizuno M, Miura T, Tomonari T, Kato Y, et al. Angiotensin receptor blockers shift the circadian rhythm of blood pressure by suppressing tubular sodium reabsorption. Am J Physiol Renal Physiol 2011; 301:F953-F957.
19. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1):S1-S266.
20. Ono M, Fukuda M, Miura T, Mizuno M, Kato Y, Sato R, et al. Predictors of proteinuria reduction by monotherapy with an angiotensin receptor blocker, olmesartan. J Renin Angiotensin Aldosterone Syst 2012; 13:239-243.
21. Silkensen JR, Kasiske BL. Laboratory assessment of kidney disease clearance, urinalysis, and kidney biopsy: techniques to measure urine protein. In: Brenner BM, editor. Brenner & Rector's The kidney, 7th ed. Philadelphia: Saunders; 2004. pp. 1123-1126.
22. Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992; 327:1912-1918.
23. Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, et al. Sympathetic nerve activity in end-stage renal disease. Circulation 2002; 106:1974-1979.
24. Klein IH, Ligtenberg G, Neumann J, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol 2003; 14:3239-3244.
25. Grassi G, Vailati S, Bertinieri G, Seravalle G, Stella ML, Dell'Oro R, Mancia G. Heart rate as marker of sympathetic activity. J Hypertens 1998; 16:1635-1639.
26. Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: a 3-year follow-up study. Circulation 2000; 102:1536-1541.
27. Masuda S, Tamura K, Wakui H, Kanaoka T, Ohsawa M, Maeda A, et al. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. Hypertens Res 2009; 32:950-955.
28. Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. JAmSoc Nephrol 2004; 15:524-537.
29. Schlaich MP, Socratous F, Hennebry S, Eikelis N, Lambert EA, Straznicky N, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol 2009; 20:933-939.